Brigette Roberts, M.D.

Dr. Brigette Roberts is a Board Member and Chief Executive Officer of IRulya Therapeutics. Previously, she served as Chief Executive Officer and a member of the Board of Directors of Orphai Therapeutics, where she built a differentiated pulmonary franchise centered on LAM-001, an inhaled formulation of rapamycin for pulmonary vascular and fibrotic lung diseases. Under her leadership, the company initiated two Phase 2 clinical studies, advanced LAM-001 as a potential disease-modifying therapy, secured U.S. and EU orphan drug designations across multiple indications, and raised more than $45 million in private financing. She also led the company’s transformation from AI Therapeutics to Orphai Therapeutics as part of its strategic evolution and growth.

Prior to her operating leadership roles, Dr. Roberts spent 15 years as a healthcare investor and portfolio manager at Third Point, CDP Capital, Angel Lane Principal Strategies, and DKR Capital. She also founded the healthcare fund YYC Capital. Her investment career included activist investing and board service at Ligand Pharmaceuticals. She was recognized in Fortune’s “40 Under 40: Ones to Watch” and by Business Insider for managing a top-performing healthcare fund while in her thirties.

Dr. Roberts earned a B.A. in Physics & Chemistry from Harvard University and an M.D. from New York University. She brings a unique combination of scientific expertise, capital markets experience, and executive leadership to IRulya Therapeutics, with a focus on advancing innovative therapies for patients with significant unmet medical needs.